Tenapanor for Constipation in Parkinson's Disease
This study is investigating tenapanor as a potential treatment for constipation linked to synucleinopathy (a group of brain disorders including Parkinson's disease). Researchers want to see if tenapanor can help people with Parkinson's disease who experience constipation. You might be able to join if you are between 50 and 89 years old, have a Parkinson's diagnosis, and have experienced frequent constipation in the past six months. The main goal is to see if tenapanor increases the number of complete spontaneous bowel movements (CSBMs) over 6 to 12 weeks. The current recruitment status is unclear.
- Study design
- This is a randomized, double-blind, placebo-controlled study, meaning participants will be randomly assigned to receive either tenapanor or a placebo (an inactive substance), and neither you nor your doctor will know which you are receiving. The study plans to enroll 30 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 6 of 12 weeks, suggesting follow-up for at least 12 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Tenapanor in Synucleinopathy-Related Constipation
At a glance
Conditions
NCT06460038
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Cedar Valley Digestive Health Center
Waterloo, Iowastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Richard A. Manfready, MD, AM, FACP · PRINCIPAL_INVESTIGATOR · Cedar Valley Digestive Health Center
- Ravindra Mallavarapu, MD · STUDY_CHAIR · Cedar Valley Digestive Health Center
- Harichandana Punukula, PharmD, MS · STUDY_DIRECTOR · Cedar Valley Digestive Health Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Complete spontaneous bowel movements (CSBM)6 of 12 weeks
Our primary endpoint will be CSBM response, defined as an increase of at least one CSBM per week compared to baseline for at least 6 of the 12 treatment weeks. A CSBM is defined as a bowel movement that occurs naturally and is accompanied by a feeling of complete evacuation